Algorithms to Define Abnormal Growth in Children: External Validation and Head-To-Head Comparison.


Journal

The Journal of clinical endocrinology and metabolism
ISSN: 1945-7197
Titre abrégé: J Clin Endocrinol Metab
Pays: United States
ID NLM: 0375362

Informations de publication

Date de publication:
01 02 2019
Historique:
received: 03 04 2018
accepted: 15 08 2018
pubmed: 24 8 2018
medline: 18 12 2019
entrez: 24 8 2018
Statut: ppublish

Résumé

Growth monitoring of apparently healthy children aims at early detection of serious conditions by use of both clinical expertise and algorithms that define abnormal growth. The seven existing algorithms provide contradictory definitions of growth abnormality and have a low level of validation. An external validation study with head-to-head comparison of the seven algorithms combined with study of the impact of use of the World Health Organization (WHO) vs national growth charts on algorithm performance. With a case-referent approach, we retrospectively applied all algorithms to growth data for children with Turner syndrome, GH deficiency, or celiac disease (n = 341) as well as apparently healthy children (n = 3406). Sensitivity, specificity, and theoretical reduction in time to diagnosis for each algorithm were calculated for each condition by using the WHO or national growth charts. Among the two algorithms with high specificity (>98%), the Grote clinical decision rule had higher sensitivity than the Coventry consensus (4.6% to 54% vs 0% to 8.9%, P < 0.05) and offered better theoretical reduction in time to diagnosis (median: 0.0 to 0.9 years vs 0 years, P < 0.05). Sensitivity values were significantly higher with the WHO than national growth charts at the expense of specificity. The Grote clinical decision rule had the best performance for early detection of the three studied diseases, but its limited potential for reducing time to diagnosis suggests the need for better-performing algorithms based on appropriate growth charts.

Sections du résumé

Background
Growth monitoring of apparently healthy children aims at early detection of serious conditions by use of both clinical expertise and algorithms that define abnormal growth. The seven existing algorithms provide contradictory definitions of growth abnormality and have a low level of validation.
Objective
An external validation study with head-to-head comparison of the seven algorithms combined with study of the impact of use of the World Health Organization (WHO) vs national growth charts on algorithm performance.
Design
With a case-referent approach, we retrospectively applied all algorithms to growth data for children with Turner syndrome, GH deficiency, or celiac disease (n = 341) as well as apparently healthy children (n = 3406). Sensitivity, specificity, and theoretical reduction in time to diagnosis for each algorithm were calculated for each condition by using the WHO or national growth charts.
Results
Among the two algorithms with high specificity (>98%), the Grote clinical decision rule had higher sensitivity than the Coventry consensus (4.6% to 54% vs 0% to 8.9%, P < 0.05) and offered better theoretical reduction in time to diagnosis (median: 0.0 to 0.9 years vs 0 years, P < 0.05). Sensitivity values were significantly higher with the WHO than national growth charts at the expense of specificity.
Conclusion
The Grote clinical decision rule had the best performance for early detection of the three studied diseases, but its limited potential for reducing time to diagnosis suggests the need for better-performing algorithms based on appropriate growth charts.

Identifiants

pubmed: 30137417
pii: 5075999
doi: 10.1210/jc.2018-00723
doi:

Substances chimiques

Human Growth Hormone 12629-01-5

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't Validation Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

241-249

Commentaires et corrections

Type : CommentIn
Type : CommentIn
Type : ErratumIn

Auteurs

Pauline Scherdel (P)

INSERM, UMR1153 Epidemiology and Biostatistics Sorbonne Paris Cité Center, Early Origins of the Child's Health and Development Team, Paris Descartes University, Villejuif, France.
INSERM, UMR1153 Epidemiology and Biostatistics Sorbonne Paris Cité Center, Obstetrical, Perinatal, and Pediatric Epidemiology Research Team, Paris Descartes University, Paris, France.

Soraya Matczak (S)

Department of General Pediatrics, Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris, Paris Descartes University, Paris, France.

Juliane Léger (J)

Department of Pediatric Endocrinology and Diabetology, Robert-Debré Hospital, Assistance Publique-Hôpitaux de Paris, Paris Diderot University, Reference Centre for Endocrine Growth and Development Diseases, Paris, France.

Christine Martinez-Vinson (C)

Department of Pediatric Gastroenterology and Nutrition, Robert-Debré Hospital, Assistance Publique-Hôpitaux de Paris, Paris-Diderot University, Paris, France.

Olivier Goulet (O)

Department of Pediatric Gastroenterology-Hepatology and Nutrition, Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris, Paris Descartes University, Paris, France.

Raja Brauner (R)

Unité d'Endocrinologie Pédiatrique, Fondation Ophtalmologique Adolphe de Rothschild, Paris Descartes University, Paris, France.

Sophie Nicklaus (S)

Centre des Sciences du Goût et de l'Alimentation, AgroSupDijon Centre National de la Recherche Scientifique, Institut National de la Recherche Agronomique, Université Bourgogne Franche-Comté, Dijon, France.

Matthieu Resche-Rigon (M)

INSERM, UMR1153 Epidemiology and Biostatistics Sorbonne Paris Cité Center, Epidémiologie Clinique, Statistique, pour la Recherche en Santé, Service de Biostatistique et Information Médicale, Saint-Louis Hospital, Paris Diderot University, Paris, France.

Martin Chalumeau (M)

INSERM, UMR1153 Epidemiology and Biostatistics Sorbonne Paris Cité Center, Obstetrical, Perinatal, and Pediatric Epidemiology Research Team, Paris Descartes University, Paris, France.
Department of General Pediatrics, Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris, Paris Descartes University, Paris, France.

Barbara Heude (B)

INSERM, UMR1153 Epidemiology and Biostatistics Sorbonne Paris Cité Center, Early Origins of the Child's Health and Development Team, Paris Descartes University, Villejuif, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH